Navigation Links
Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Date:8/19/2007

http://www.phosphagenics.com

About Phosphagenics' Transdermal Carrier Technology

Phosphagenics' patented transdermal carrier technology (TPM) utilises natural dermal transport mechanisms to rapidly transport small and large molecules across the skin without disrupting or damaging its surface.

The Company believes that the key advantages of this delivery system includes the fact that it possesses anti-inflammatory and anti-erythema properties, thus minimising skin irritation, and has the ability to provide a sustained systemic delivery of a wide range of drugs - ranging from relatively small molecules (e.g. morphine, fentanyl, oxycodone, atropine, estradiol, testosterone) to large molecules (e.g. insulin and PTH) - from a single application. Additionally, the TPM delivery technology can be cost- effectively manufactured in a wide range of presentations (e.g. gel, paste, liquid and powder) adding value to existing pharmaceuticals.

Safe Harbor Statement

This press release contains forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from the Phosphagenics' expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations.


'/>"/>
SOURCE Phosphagenics Limited

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced today the presentation of new ... its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine ... various temperatures up to and including 55 degrees C. ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...
(Date:12/4/2009)... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New ... Administration seeking approval to market its 8mg ramelteon tablets ... Takeda Pharmaceutical Company Limited. Watson,s 8mg ramelteon tablet ...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Baucus Bill Imposes Additional Tax Burdens on Nonprofit Hospitals 57437 1Baucus Bill Imposes Additional Tax Burdens on Nonprofit Hospitals 57437 2Senate Finance Committee Cuts Home Medical Equipment in Reform Package 57435 1Senate Finance Committee Cuts Home Medical Equipment in Reform Package 57435 2Aethlon Medical Inc Announces Annual Meeting Results 14111 1Aethlon Medical Inc Announces Annual Meeting Results 14111 2Aethlon Medical Inc Announces Annual Meeting Results 14111 3
... Achieved at Least 75 Percent Improvement in Psoriasis,Signs ... Five Dosing Groups, More,Than Half Achieved 90 Percent ... -- New,Phase II study results show Abbott's investigational ... patients treated. At 12 weeks, nine out of ...
... Studies Suggest FTY720 Mechanisms in Multiple,Sclerosis May Include ... studies suggest FTY720 stimulates cells,that may help reduce ... multiple sclerosis , · Separately, analyses from the ... the proportion of,patients with clinical depression was significantly ...
Other Medicine Technology:Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 3Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9
(Date:12/5/2009)... What: Cuts for a Cause ,, ... cancer and other terminal illnesses affecting children. All proceeds from ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors ... restaurant in Falls Church for all guests. Hoa Lai, a ...
(Date:12/5/2009)... experts advise , , SATURDAY, Dec. 5 (HealthDay News) -- ... can have bad reactions to certain holiday traditions and ... wheezing, according to the American College of Allergy, Asthma ... live evergreens may choose to decorate with artificial plants, ...
(Date:12/5/2009)... by the National Association of Certified Professional Midwives ... for Midwifery (CfM), International Center for Traditional Childbearing ... the Midwifery Education Accreditation Council (MEAC). To ... Campaign to secure federal recognition of CPMs language ...
(Date:12/4/2009)... YORK, Dec. 4 Thousands of KPMG LLP employees came ... in a community service event which combines the audit, tax ... ,, "This national service day reflects our firm,s long history ... the spirit of caring to brighten the holidays for some ...
(Date:12/4/2009)... SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, ... announced the execution of a purchase and sale agreement ... in San Angelo, Texas, Corsicana, Texas, and Fort Wayne, ... acquisition is subject to the satisfaction of a number ...
Breaking Medicine News(10 mins):Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2
... offset the effect, study suggests , , TUESDAY, Dec. 30 ... be a major mechanism contributing to normal, age-related cognitive ... to change: rising blood glucose levels, which means that ... the December issue of Annals of Neurology ...
... ) announces the following Webcast: , , What: ... January 6, 2009 @ 11:00 EST, Where: http://www.videonewswire.com/event.asp?id=53900 , ... log on to the web at the address, ... Maynard of Neogen Corporation, +1-800-234-5333., , If you are ...
... LONDON, December 30 , - ... Give Your Child,GBP15,500 on Their 18th Birthday , ... http://www.thechildrensmutual.co.uk ) is encouraging all parents who decide,to give up ... that they will save towards their children,s futures. , ...
... The National Committee for Quality,Assurance and the American ... Terry Spears Barnett, M.D., Mirela Sturzu,M.D., Rudolf Teschan, ... Diabetes Physician Recognition Program for providing quality care ... Drs. Hany and Zaki practice at the Aurora ...
... 29 Curious about your child,s diet,preventing injury, ... daughter has a sports-related,injury? , ... sports coaches, parents and,athletes focused on education, communication ... (PEAKOrthopedics.com) to answer these questions,through an online, sports ...
... and Blue Shield of Oklahoma announced today the addition ... next policy year. This change will not in any ... been available to children with autism. Blue Cross and ... in the benefits and coverage of certain autism-related medically ...
Other Medicine News:Health News:Rising Blood Sugar May Harm the Aging Brain 2Health News:Rising Blood Sugar May Harm the Aging Brain 3Health News:Urging New Year Quitters to Invest in Their Family's Futures 2Health News:Aurora Physicians Receive National Recognition for Quality Diabetes Care 2Health News:SportZu.tv Partners With PEAK Orthopedics & Spine to Launch an Online Sports Doctor's Office 2Health News:Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: